Tiziana Life Sciences Ltd Dossier
Qualitative Analysis
Business overview
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on the discovery and development of novel molecules to treat human diseases in inflammation and immunology. The company's primary focus is on alternative, non-invasive routes of immunotherapy, specifically targeting neurodegenerative and neuroinflammatory diseases. Its lead clinical candidate is intranasal foralumab (TZLS-401), a fully human anti-CD3 monoclonal antibody designed to stimulate regulatory T cells (Tregs) and reduce microglial activation directly in the brain. This candidate is being actively developed for Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Multiple System Atrophy (MSA), Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing core resources on the clinical advancement of lead candidate intranasal foralumab, a fully human anti-CD3 monoclonal antibody, across multiple neurodegenerative and neuroinflammatory indications including na-SPMS, Alzheimer's Disease, and Multiple System Atrophy (MSA).
Expected impact: Establishment of a first-in-class alternative route of immunotherapy with improved safety and localized efficacy compared to intravenous delivery.
Spinning out the fully human anti-IL-6R monoclonal antibody TZLS-501 and related assets into a separate, publicly traded immunology-focused company to enhance strategic focus and unlock shareholder value.
Expected impact: Allows Tiziana to remain fully focused on its lead asset foralumab while capturing the strategic value of the IL-6 pathway asset.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. Collaboration to optimize, scale up, and manufacture intranasal foralumab in a nasal spray device for clinical trials and potential commercialization.
Terms: Not fully disclosed; fee-for-service and milestone-based development agreement.